Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Karp

Showing results (81-90 of 405) with videos related to

Pageof 41
Sort By:
The Journal of Foot Surgery|January 1, 1981
The use of freeze-dried bone allografts: a review of the literature with special emphasis on their use in treatment of solitary bone cystsS L Chaney, N E Karp
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Development of therapeutic agents for older patients with acute myelogenous leukemiaChristopher S Hourigan, Judith E Karp
Obstetrics and Gynecology|August 1, 1981
Azathioprine teratogenicity: review of the literature and case reportR A Williamson, L E Karp
Seminars in Oncology|February 1, 1997
The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and preventionJ E Karp, M A Smith
The American Journal of Physiology|November 1, 1974
Fibrinogen-fibrin degradation products and fibrinolysis following exercise in humansJ E Karp, W R Bell
Annals of Hematology|May 6, 2004
Farnesyltransferase inhibitors (FTIs) in myeloid malignanciesJ E Karp, J E Lancet
Oncology (Williston Park, N.Y.)|September 1, 2005
Farnesyl transferase inhibitors in myeloid disordersJeffrey E Lancet, Judith E Karp
Leukemia Research|February 24, 2006
Developmental clinical trials: building one step at a timeJudith E Karp, B Douglas Smith
Nature Reviews. Clinical Oncology|June 27, 2013
Minimal residual disease in acute myeloid leukaemiaChristopher S Hourigan, Judith E Karp
Cancer|December 8, 2015
Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancerJudith E Karp, Antonio C Wolff
Pageof 41

Showing results (81-90 of 405) with videos related to

Sort By:
Pageof 41
The Journal of Foot Surgery|January 1, 1981
The use of freeze-dried bone allografts: a review of the literature with special emphasis on their use in treatment of solitary bone cystsS L Chaney, N E Karp
Current Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Development of therapeutic agents for older patients with acute myelogenous leukemiaChristopher S Hourigan, Judith E Karp
Obstetrics and Gynecology|August 1, 1981
Azathioprine teratogenicity: review of the literature and case reportR A Williamson, L E Karp
Seminars in Oncology|February 1, 1997
The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and preventionJ E Karp, M A Smith
The American Journal of Physiology|November 1, 1974
Fibrinogen-fibrin degradation products and fibrinolysis following exercise in humansJ E Karp, W R Bell
Annals of Hematology|May 6, 2004
Farnesyltransferase inhibitors (FTIs) in myeloid malignanciesJ E Karp, J E Lancet
Oncology (Williston Park, N.Y.)|September 1, 2005
Farnesyl transferase inhibitors in myeloid disordersJeffrey E Lancet, Judith E Karp
Leukemia Research|February 24, 2006
Developmental clinical trials: building one step at a timeJudith E Karp, B Douglas Smith
Nature Reviews. Clinical Oncology|June 27, 2013
Minimal residual disease in acute myeloid leukaemiaChristopher S Hourigan, Judith E Karp
Cancer|December 8, 2015
Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancerJudith E Karp, Antonio C Wolff
Pageof 41